Monoclonal Antibodies and Other Novel Therapeutics in COVID-19 Treatment - Webinar Series May 26, 2021 Webinar – Monoclonal Antibody Therapy for COVID-19: What You Need to Know - ONLINE

Activity Description

This series of three 90-minute webinars features Mayo Clinic experts discussing monoclonal antibodies and other novel therapeutics in COVID-19 treatment. Webinar recordings will be available within 48-hours following live streams.

On **Wednesday, May 26,** Mayo Clinic experts discussed monoclonal antibody treatment in depth, including what it is, how it works, and where it fits in the current treatment of COVID-19.

Target Audience

Healthcare providers in all specialties who are being impacted by COVID-19, including physicians, research scientists, physician assistants, nurse practitioners, nurses, and caregivers with a particular interest in prevention, treatment, and patient care.

Learning Objectives

Upon conclusion of this segment, participants should be able to:

- Provide updates on mAb emergency use authorizations in USA
- Review the process for the development and maintenance of MCF's treatment algorithm focusing on mAb for outpatients and hospitalized COVID individuals
- Review the Mayo Clinic Florida experience using monoclonal therapy in COVID patients
- Identify those at higher risk of disease progression who may benefit from early administration of mAb
- Address logistical requirements for administration of mAb and the operation of an infusion COVID center.
- Discuss a multidiscipline approach for COVID management and research clinical trial selection of patients at MCF
- Recognize SARS-CoV-2 variants impact on mAb's future

Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 1.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AOA

The American Osteopathic Association designates this program for a maximum of 1.50 AOA Category 2-A credits.

Other Healthcare Professionals

A certificate of attendance will be provided to other healthcare professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Disclosure Summary

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Financial relationship(s):

Devyani Lal, M.D.

Consultant for GlaxoSmithKline (Participation as a speaker in an industry-sponsored educational panel.)

No Financial relationship(s):

Lisa Brumble, M.D.

Claudia R. Libertin, M.D.

Kathleen (Kate) A. Rottman Pietrzak, Pharm.D., R.Ph.

Leigh L. Speicher, M.D., M.P.H.

Reference to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Lisa Brumble, M.D.

Genentech Tocilizumab

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to **review disclosures**.

Mayo Disclaimer

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

Prerequisites for Participation

There are no prerequisites needed prior to participating in this education activity.

How to Obtain Credit

Complete the assessment and submit for credit.

Method of Participation

Participation in this activity consists of participating in the live webinar or online course, completing the assessment, evaluation, and claiming credit.

Release and Expiration Dates

Release Date: May 28, 2021 Expiration Date: May 28, 2022

Faculty and Course Director Listing and Credentials

Course Director: Devyani Lal, M.D.

Faculty:

Lisa Brumble, M.D. Claudia R. Libertin, M.D. Kathleen (Kate) A. Rottman Pietrzak, Pharm.D., R.Ph. Leigh L. Speicher, M.D., M.P.H.

Copyright

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2021.

Commercial Support

This educational activity is supported in part by an independent medical education grant from

Eli Lilly and Company

and is in accordance with ACCME guidelines.